Dharmacon, Abbott Collaborate on siRNA Therapeutics
Lafayette, Colorado-based Dharmacon has inked a deal with Abbott, to develop new therapeutic agents. The firms said today that they will work together on gene silencing technology of RNA interference (RNAi), initially focused on oncology. The two will use Dharmacon's siRNA chemistries and technologies to optimize siRNAs for therapeutic use, with Abbott managing the drug discovery and development process, along with commercialization of products. Terms of the deal were not disclosed. Dharmacon is a unit of Fisher Biosciences, which purchased the company in 2004.
posted on Thursday, July 6, 2006
Related stories:
> Merck Buys Sirna Therapeutics
> Allos Therapeutics Appoints New President and CEO
> Insys Therapeutics Files For IPO
> Intelliden Expands Management Team
> Q Therapeutics Gets Investment
Techrockies.com Home